MARKET

CGON

CGON

CG Oncology, Inc.
NASDAQ
67.15
-1.61
-2.34%
After Hours: 66.00 -1.15 -1.71% 19:30 09/25 EDT
OPEN
69.32
PREV CLOSE
68.76
HIGH
70.05
LOW
66.76
VOLUME
1.18M
TURNOVER
--
52 WEEK HIGH
80.97
52 WEEK LOW
35.64
MARKET CAP
5.95B
P/E (TTM)
-24.9119
1D
5D
1M
3M
1Y
5Y
1D
Notable Tuesday Option Activity: ASTS, ILPT, CGON
NASDAQ · 3d ago
SBIO: Big Pharma Needs What This Fund Owns
Seeking Alpha · 4d ago
Weekly Report: what happened at CGON last week (0914-0918)?
Weekly Report · 5d ago
Weekly Report: what happened at CGON last week (0907-0911)?
Weekly Report · 09/14 09:13
Analysts’ Top Healthcare Picks: CG Oncology, Inc. (CGON), Opus Genetics (IRD)
TipRanks · 09/10 12:50
Weekly Report: what happened at CGON last week (0831-0904)?
Weekly Report · 09/07 09:12
Weekly Report: what happened at CGON last week (0824-0828)?
Weekly Report · 08/31 09:14
Regulatory Momentum Around Oncolytic Virus Therapy Could Be A Game Changer For CG Oncology (CGON)
Simply Wall St · 08/27 04:43
More
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Webull offers CG Oncology Inc stock information, including NASDAQ: CGON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGON stock methods without spending real money on the virtual paper trading platform.